Abstracts tagged "anti-TNF therapy"

Abstract Number: 598 • 2018 ACR/ARHP Annual Meeting
Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study
Naohiro Sugitani^1,2, Eiichi Tanaka¹, Eisuke Inoue^1,3, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai¹, Rei Yamaguchi¹, Yoko Shimizu¹, Naoki Sugimoto¹, Katsunori Ikari¹, Ayako Nakajima^1,2, Atsuo Taniguchi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ³Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Certolizumab-pegol (CZP) is a sixth antitumor necrosis factor inhibitor for rheumatoid arthritis (RA) in Japan. Several clinical trials were conducted to evaluate the efficacy…
Abstract Number: 2790 • 2018 ACR/ARHP Annual Meeting
Screening of Patients with Adult-Onset Idiopathic Polyarteritis Nodosa for Deficiency of Adenosine Deaminase 2
Oskar Schnappauf¹, Monique Stoffels², Ivona Aksentijevich², Daniel L. Kastner², Peter C. Grayson³, David Cuthbertson⁴, Simon Carette⁵, Sharon A. Chung⁶, Lindsy J. Forbess⁷, Nader A. Khalidi⁸, Curry L. Koening⁹, Carol Langford¹⁰, Carol A. McAlear¹¹, Paul A. Monach¹², Larry W. Moreland¹³, Christian Pagnoux¹⁴, Philip Seo¹⁵, Jason Springer¹⁶, Antoine G. Sreih¹⁷, Kenneth J. Warrington¹⁸, Steven R. Ytterberg¹⁸ and Peter A. Merkel¹⁹, ¹NHGRI, National Institutes of Health, Bethesda, MD, ²Metabolic, Cardiovascular, and Inflammatory Disease Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, ⁴Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁶Russell/Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatology, McMaster University, Hamilton, ON, Canada, ⁹Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹⁰Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁴Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹⁵Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁶Department of Internal Medicine, The University of Kansas Medical Center, Division of Allergy, Clinical Immunology & Rheumatology, Kansas City, KS, ¹⁷Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ¹⁹Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is the first described type of monogenic vasculitis. Patients usually present in childhood, but age of onset, disease…
Abstract Number: 618 • 2018 ACR/ARHP Annual Meeting
Blood Lymphocytes Subtypes As Biomarkers for Early Identification of Optimal Responders to Anti-TNF Treatment in Rheumatoid Arthritis
Cristina Sobrino¹, Borja Hernández-Breijo², Israel Gañán-Nieto¹, Carlota García-Hoz¹, Victoria Navarro-Compán², Ana Martínez², Javier Bachiller¹, María Gema Bonilla Hernán², Dora Pascual-Salcedo², Garbiñe Roy¹, Mónica Vázquez¹, Alejandro Balsa², Luisa María Villar¹, Chamaida Plasencia² and Eulalia Rodríguez-Martín¹, ¹Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, ²Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain
Background/Purpose: TNF inhibitors (TNFi) are the most common biologicalagents used as disease-modifying treatment in rheumatoid arthritis (RA). Although these drugs have contributed to change the…
Abstract Number: 2823 • 2018 ACR/ARHP Annual Meeting
Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor
Daniela Santos Faria¹, Mónica Eusébio², Joana Leite Silva³, Joana Ramos Rodrigues¹, Joana Sousa Neves¹, Ana Catarina Duarte⁴, Carina Lopes⁵, Ana Valido⁶, Joana Dinis⁶, João Freitas⁷, Mariana Santiago⁷, Raquel Ferreira⁸, Sara Ganhão⁹, Luís Cunha Miranda¹⁰, Daniela Peixoto¹, Filipa Teixeira¹, Sérgio Alcino¹, Carmo Afonso¹, José Tavares Costa³ and Maria José Santos¹¹, ¹Rheumatology, ULSAM, Ponte de Lima, Portugal, ²Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, LIsboa, Portugal, ³Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ⁴Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ⁵Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ⁶Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁷Rheumatology, Centro Hospitalar e Universitário de Coimbra, CHUC-EPE, Coimbra, Portugal, ⁸Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ⁹Rheumatology, Centro Hospitalar de São João, Porto, Portugal, ¹⁰Instituto Português de Reumatologia, Lisbon, Portugal, ¹¹Reuma.pt, Almada, Portugal, Almada, Portugal
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are highly effective treatments for active Rheumatoid Arthritis (RA). However, up to 40% of patients either fail to respond…
Abstract Number: 639 • 2018 ACR/ARHP Annual Meeting
Is a Primary Good Response to Nsaids Predictive of the Subsequent Response to the First TNF Inhibitor in Patients with Early Axial Spondyloarthritis ?
Loukianos Couvaras¹, Daniel Wendling², Vanessa Pauly³, Vincent Pradel⁴, Anna Molto⁵, Pierre Lafforgue¹ and Thao Pham⁶, ¹Rheumatology, Aix-Marseille University, APHM, Marseille, France, ²service de rhumatologie, CHU J Minjoz, Besancon, France, ³Public Health, Aix-Marseille university, AP-HM, Marseille, France, ⁴Public Health, APHM, Marseille, France, ⁵Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁶Rheumatology Department, Aix-Marseille University, APHM, Marseille, France
Background/Purpose: Good response to NSAIDs is a SpA feature included in classification criteria for axial spondyloarthritis (axSpA). Among patients eligible for a TNF inhibitor (TNFi),…
Abstract Number: 2829 • 2018 ACR/ARHP Annual Meeting
The Response to TNF-Blockers Treatment of Spa Patients Is Influenced By the Interplay between HLA-B27 and Gut Microbiota Composition at Baseline
Marie Vallier¹, Maxime Dougados², Stephanie Ferreira³, Silvia Menegatti⁴, Elisabetta Bianchi⁵, Lars Rogge⁵, Mathias Chamaillard¹ and Corinne Miceli-Richard², ¹CIIL - U1019 - NLRII, Institut Pasteur, Lille, France, ²Rheumatology Department, Paris Descartes University, Paris, France, ³Genoscreen, Lille, France, ⁴Immunology, Immunoregulation Unit, Institut Pasteur, Paris, France, ⁵Immunology, Institut Pasteur, Paris, France
Background/Purpose: The response to TNF-blockers in axial spondyloarthritis (AxSpA) is at least partially influenced by HLA-B27 through a still poorly understood mechanism. Given that HLA-B27…
Abstract Number: 921 • 2018 ACR/ARHP Annual Meeting
Multi-Omics Analysis Identifies a Gene Signature Associated with the Clinical Response to Anti-TNF Therapy in Rheumatoid Arthritis
Adrià Aterido¹, Jesús Tornero², Francisco J Blanco³, Benjamin Fernandez Gutierrez⁴, Antonio Gonzalez⁵, Juan D. Cañete⁶, Joan Maymó⁷, Mercedes Alperi-López⁸, Alejandro Olivé-Marqués⁹, Hector Corominas¹⁰, Víctor Martínez-Taboada¹¹, Isidoro Gonzalez-Alvaro¹², Antonio Fernandez-Nebro¹³, Alba Erra¹⁴, Simón Sánchez-Fernández¹⁵, María López-Lasanta¹, Mireia López-Corbeto¹, Raül Tortosa¹, Laia Codó¹⁶, Sara Marsal¹ and Antonio Julià¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ³Rheumatology Department, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁴Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ⁵Laboratorio Investigación 10 and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁶Rheumatology Service, Hospital Clínic of Barcelona, Barcelona, Spain, ⁷Rheumatology Department, Hospital del Mar, Barcelona, Spain, ⁸Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ¹¹Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ¹³UGC de Reumatología, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga Departamento de Medicina y Dermatología, Universidad de Málaga, MÁLAGA, Spain, ¹⁴Rheumatology Service, Hospital San Rafael, Barcelona, Spain, ¹⁵Rheumatology Department, Hospital General La Mancha Centro, Ciudad Real, Spain, ¹⁶Life Sciences Department, Barcelona Supercomputing Centre, Barcelona, Spain
Background/Purpose: Rheumatoid arthritis (RA) is the most common inflammatory arthritis affecting up to 1% of the population. Tumor Necrosis Factor (TNF) inhibitors have significantly improved…
Abstract Number: 2831 • 2018 ACR/ARHP Annual Meeting
High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis
Philippe Carron¹, Gaëlle Varkas², Thomas Renson³, Roos Colman⁴, Dirk Elewaut⁵ and Filip van Den Bosch⁶, ¹Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ²Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ³Department of Rheumatology, Ghent University Hospital, Ghent, 9000, Belgium, ⁴Department of Public Health, Ghent University, Ghent, Belgium, Biostatistics Unit,Ghent University, Ghent, Belgium, Ghent, Belgium, ⁵Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ⁶Rheumatology, Ghent University Hospital and VIB Ghent University, Gent, Belgium
Background/Purpose: Treatment with TNFi in early stages of peripheral Spondyloarthritis (pSpA) results in higher rates of clinical remission, compared to treatment in more longstanding disease.…
Abstract Number: 961 • 2018 ACR/ARHP Annual Meeting
The Association of Biologic Drug-Levels with Infection Risk: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Meghna Jani¹, William G Dixon¹, Mark Lunt¹, Diederik De Cock¹, John Isaacs², Ann Morgan³, Kath Watson¹, Anthony G. Wilson⁴, Anne Barton^5,6 and Kimme L. Hyrich^1,5, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ⁴UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland, ⁵National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom
Background/Purpose: High dose tumour necrosis factor inhibitor (TNFi) drugs are associated with an increased serious infection (SI) risk[1]. It is feasible that high biologic…
Abstract Number: 2862 • 2018 ACR/ARHP Annual Meeting
Magnitude of Response to TNF Inhibitors in Children with Spondyloarthritis and Sacroiliitis
Rosemary Peterson¹, Rui Xiao², Timothy G. Brandon³, David M. Biko⁴, Michael Francavilla⁴, Nancy A. Chauvin⁵ and Pamela F. Weiss⁶, ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Radiology, Penn State Hershey Medical Center, Hershey, PA, ⁶Pediatrics, Children's Hospital Philadelphia, Philadelphia, PA
Background/Purpose: We aimed to quantify the magnitude of biologic effect on sacroiliitis in juvenile SpA by comparing the change in the Spondyloarthritis Research Consortium of…
Abstract Number: 1234 • 2018 ACR/ARHP Annual Meeting
Incidence of Conversion of Screening Tests for M. Tuberculosis (PPD, GIF-release assay) in a Metropolitan Cohort of Patients Treated with TNF-α Inhibitors
Hung Trinh and Darren Tabechian, Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Tumor necrosis factor alpha (TNF-α) inhibitors are used to reduce the inflammatory process in many autoimmune diseases. Due to the risk of reactivation of…
Abstract Number: 2877 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas¹, Gregory St. John², Carol J. Etzel¹, Stefano Fiore³, Taylor Blachley¹, Toshio Kimura², Rajeshwari Punekar³, Kelechi Emeanuru⁴, Susan Boklage² and Joel Kremer^1,5, ¹Corrona LLC, Waltham, MA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi, Bridgewater, NJ, ⁴Corrona, LLC, Waltham, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: RA patients who are intolerant or have an inadequate response to conventional synthetic DMARDs (csDMARDs) can be treated with a biologic DMARD (bDMARD). Tumor…
Abstract Number: 1450 • 2018 ACR/ARHP Annual Meeting
Clinical Radiology Reports Are Unreliable for Assessment of Radiographic Structural Progression in US Veterans with Rheumatoid Arthritis Initiating Tumor Necrosis Factor Inhibitor Therapy
Kevin R. Lammert¹, Alan R. Erickson², Brian C. Sauer¹ and Grant W. Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatologists rely on hand radiograph findings including bone erosions (BE) and joint space narrowing (JSN) to make treatment decisions for patients with rheumatoid arthritis…
Abstract Number: 2879 • 2018 ACR/ARHP Annual Meeting
Plasma IL-23 and IL-25 Predict Response to Anti-TNF-α Therapy in Rheumatoid Arthritis
Niamh Fanning¹, Melanie J Millier², John Highton², Christopher Frampton³, Paul A Hessian² and Lisa K. Stamp³, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Department of Medicine, University of Otago, Dunedin, New Zealand, ³University of Otago, Christchurch, New Zealand
Background/Purpose: TNF-α inhibitors are among the most widely used biological-DMARDs in rheumatoid arthritis (RA). Means to predict response would allow for a more effective, targeted…
Abstract Number: 1497 • 2018 ACR/ARHP Annual Meeting
PRISM-RA: A Personalized Medicine Test That Accurately Predicts Rheumatoid Arthritis Patients Who Will Not Respond Adequately to Tumor Necrosis Factor Inhibitors
Keith Johnson, Nancy Schoenbrunner and Dina Ghiassian, Scipher Medicine Inc, Waltham, MA
Background/Purpose: Rheumatoid arthritis (RA) is a complex disease affecting about 1.3M adults in the US. The patient population is very heterogeneous; no single drug mechanism…

« Previous Page
1
…
3
4
5
6
7
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].